Evidence map›Paper›PMID 32204695›Full record

ArticleJournal of neurodevelopmental disorders2020

Expressive language sampling as a source of outcome measures for treatment studies in fragile X syndrome: feasibility, practice effects, test-retest reliability, and construct validity.

Leonard Abbeduto, Elizabeth Berry-Kravis, Audra Sterling, Stephanie Sherman, Jamie O Edgin, Andrea McDuffie, Anne Hoffmann, Debra Hamilton, Michael Nelson, Jeannie Aschkenasy and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Expressive Language Sample Concordance With ADOS-2 Scores: Autism, Down Syndrome, Fragile X Syndrome.American journal on intellectual and developmental disabilities · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Adaptive, behavioral, and cognitive outcomes in individuals with fragile X syndrome with varying autism severity.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Consistency and reliability of automated language measures across expressive language samples in autism.Autism research : official journal of the International Society for Autism Research · 2023
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Leonard AbbedutoUC Davis MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California, 2825 50th St. Davis, Sacramento, CA, 95817, USA. LJabbeduto@ucdavis.edu.
Elizabeth Berry-KravisDepartments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, USA.
Audra SterlingWaisman Center and Department of Communication Sciences and Disorders, University of Wisconsin-Madison, Madison, USA.
Stephanie ShermanDepartment of Human Genetics, Emory University, Atlanta, USA.
Jamie O EdginDepartment of Psychology, University of Arizona, Tucson, USA.
Andrea McDuffieUC Davis MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California, 2825 50th St. Davis, Sacramento, CA, 95817, USA.
Anne HoffmannDepartments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, USA.
Debra HamiltonDepartment of Human Genetics, Emory University, Atlanta, USA.
Michael NelsonDepartments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, USA.
Jeannie AschkenasyDepartments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, USA.
Angela John ThurmanUC Davis MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California, 2825 50th St. Davis, Sacramento, CA, 95817, USA.
Rush University Medical Center · USUniversity of California, Davis · USEmory University · USUniversity of Arizona · USUniversity of Wisconsin–Madison · US

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
Research Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI JUDY A. VAN DE WATER · 2020 to 2026
$9.7M
Rodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HERTZ-PICCIOTTO, IRVA · 2013 to 2019
$8.5M
Expressive Language Sampling as an Outcome MeasureR01HD074346 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ABBEDUTO, LEONARD J. · 2013 to 2017
$3.9M
NCATS NIH HHS UL1 TR001860NICHD NIH HHS P50 HD103526NICHD NIH HHS R01 HD074346NICHD NIH HHS U54 HD079125
6 · The paper itself

Abstract

backgroundThe evaluation of treatment efficacy for individuals with fragile X syndrome (FXS) or intellectual disability (ID) more generally has been hampered by the lack of adequate outcome measures. We evaluated expressive language sampling (ELS) as a procedure for generating outcome measures for treatment research in FXS. We addressed: (a) feasibility, (b) practice effects over two administrations, (c) test-retest reliability over the repeated administrations, and (d) construct validity. We addressed these issues for the full sample as well as for subgroups defined by age, IQ, and ASD status.

methodsParticipants were 106 individuals with FXS between ages 6 and 23 years who had IQs within the range of intellectual disability (IQ < 70). ELS procedures for collecting samples in conversation and narration were followed and analyzed separately. Five measures were derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers): number of C-units per minute (talkativeness), number of different word roots (vocabulary), C-unit length in morphemes (syntax), percentage of C-units containing dysfluency (utterance planning), and percentage of C-units that were fully or partly unintelligible (articulatory quality). ELS procedures were administered twice at 4-week intervals for each participant. Standardized tests and informant reports were administered and provided measures for evaluating construct validity of ELS measures.

resultsWe found low rates of noncompliance, suggesting the task can be completed meaningfully by most individuals with FXS, although noncompliance was higher for younger, lower IQ, and more autistic participants. Minimal practice effects and strong test-retest reliability over the 4-week interval were observed for the full sample and across the range of ages, IQs, and autism symptom severity. Evidence of convergent construct validity was observed for the measures of vocabulary, syntax, and unintelligibility for the full sample and across the range of IQ and autism symptom severity, but not for participants under age 12. Conversation and narration yielded largely similar results in all analyses.

conclusionsThe findings suggest that the ELS procedures are feasible and yield measures with adequate psychometric properties for a majority of 6 to 23 years with FXS who have ID. The procedures work equally well regardless of level of ID or degree of ASD severity. The procedures, however, are more challenging and have somewhat less adequate psychometric properties for individuals with FXS under age 12.

Indexed as

Outcome Assessment, Health CareAdolescentAutistic DisorderChildFeasibility StudiesFemaleFragile X SyndromeHumansLanguage TestsMalePsychometricsReproducibility of ResultsYoung AdultClinical trialsExpressive languageFragile X syndromeOutcome measuresPsychometricstreatment

Identifiers

PMID32204695
PMCPMC7092603
OpenAlexW3012950246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.